ONCS OncoSec Medical

OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions.

Company profile

Daniel O'Connor
Fiscal year end
Former names
NetVentory Solutions, Inc.
IRS number

ONCS stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


11 Jun 21
14 Jun 21
31 Jul 21
Quarter (USD)
Apr 21 Jan 21 Oct 20 Jul 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jul 20 Jul 19 Jul 18 Jul 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 54.39M 54.39M 54.39M 54.39M 54.39M 54.39M
Cash burn (monthly) 1.98M (positive/no burn) 3.48M 3.74M 4.27M 3.56M
Cash used (since last report) 2.97M n/a 5.22M 5.61M 6.4M 5.34M
Cash remaining 51.42M n/a 49.17M 48.78M 47.99M 49.05M
Runway (months of cash) 26.0 n/a 14.1 13.0 11.3 13.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 May 21 DelAversano Robert J Common Stock Sell Dispose S No No 4.86 453 2.2K 24,980
30 Apr 21 O'Connor Daniel J. Common Stock Sell Dispose S No No 4.86 3,172 15.42K 96,097
16 Apr 21 China Grand Pharmaceutical & Healthcare Common Stock Buy Aquire P Yes No 3.45 281,968 972.79K 3,359,607
16 Apr 21 China Grand Pharmaceutical & Healthcare Common Stock Buy Aquire P Yes No 3.45 1,409,838 4.86M 16,798,036
18 Feb 21 Alpha Common Stock Aquire X No No 3.45 368,250 1.27M 1,718,251
18 Feb 21 Alpha Warrants to Purchase Common Stock Common Stock Aquire X No No 0.01 368,250 3.68K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

4.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 3 -66.7%
Opened positions 0 3 EXIT
Closed positions 2 0 NEW
Increased positions 0 0
Reduced positions 1 0 NEW
13F shares
Current Prev Q Change
Total value 11.63M 26.6M -56.3%
Total shares 1.72M 4.47M -61.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Alpha 1.72M $11.63M -9.5%
Largest transactions
Shares Bought/sold Change
Avidity Partners Management 0 -1.95M EXIT
Altium Capital Management 0 -614K EXIT
Alpha 1.72M -181K -9.5%
Content analysis
H.S. junior Avg
New words: adequate, Area, capacity, CE, clarify, clearance, EC, EEA, EU, European, expansion, extinguishment, feedback, freestanding, GenPulse, ISO, issuable, issuer, mark, Notified, Organization, outcome, pattern, population, preexisting, prerequisite, quality, recipient, resale, safely, successful, Switzerland, Task, testing, USD, version, view
Removed: Footnote, propriety, sector, unpaid


Method and device for treating microscopic residual tumors remaining in tissues following surgical resection
18 May 21
This invention concerns treating apparently normal tissue surrounding sites of cancerous tumors so as to reduce both the probability of a recurrence of cancer at and near the site of a cancerous tissue, and to reduce the amount of apparently healthy tissue that is usually excised along with the tumor, thereby providing a substantial benefit to the cancer patient by eliminating or delaying tumor recurrence and sparing normal tissue for its functionality and for avoiding unnecessary disfigurement.
Modulating Responses to Checkpoint Inhibitor Therapy
29 Apr 21
The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor.
Plasmid Constructs for Heterologous Protein Expression and Methods of Use
4 Mar 21
Provided are plasmid vector constructs encoding multiple immunomodulatory proteins where each protein or component thereof can be expressed utilizing appropriate promoters and/or translation modifiers.
Electroporation Systems, Methods, and Apparatus
7 Oct 20
Provided herein are systems, methods, and apparatus for electroporation, which may include an applicator; an endoscope, trocar or the like; a generator; and a drug delivery device.
Systems and Methods for Detecting Fault Conditions In Electroporation Therapy
5 Aug 20
Example systems, apparatuses, methods, and computer program products are disclosed for electroporating cells in a tissue using a set of voltage pulses generated by capacitor charge circuitry based on a voltage supply.